PATENT
`Attorney Docket No. 05273.0147-01
`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`Commissioner for Patents
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`Prior Application Art Unit: 1627
`
`Prior Application Examiner: Sarah PIHONAK
`
`Commissioner: This is a request for filing a
`[g) Continuation D Continuation-in-Part D Divisional Application under 37 C.F.R. § 1.53(b) of
`pending prior Application No. 11/919,678, filed October 31, 2007, of Kazuyuki FUJIHARA for
`PHARMACEUTICAL COMPOSITION.
`
`1.
`
`2.
`
`3.
`
`4.
`
`5.
`
`Enclosed is a complete copy of the prior application and drawings, as originally
`filed. The attached papers are a true copy of prior Application No. 11/919,678,
`which is a National Stage Entry of International Application
`No. PCT/JP2006/31 0571, filed May 26, 2006, which claims priority to Japanese
`Patent Application No. 2005-153508, filed May 26, 2005, the content of each of
`which is incorporated herein by reference.
`
`Certification and Request for Prioritized Examination under 37 C.F.R. § 1.102(e)
`
`A Preliminary Amendment is enclosed.
`
`A new oath or declaration is enclosed.
`
`An Application Data Sheet is enclosed.
`
`Par Pharm., Inc.
`Exhibit 1041
`Page 001
`
`

`

`

`

`

`

`PATENT
`Attorney Docket No. 05273.0147-01
`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`Commissioner for Patents
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`Prior Application Art Unit: 1627
`
`Prior Application Examiner: Sarah PIHONAK
`
`Commissioner: This is a request for filing a
`[g) Continuation D Continuation-in-Part D Divisional Application under 37 C.F.R. § 1.53(b) of
`pending prior Application No. 11/919,678, filed October 31, 2007, of Kazuyuki FUJIHARA for
`PHARMACEUTICAL COMPOSITION.
`
`1.
`
`2.
`
`3.
`
`4.
`
`5.
`
`Enclosed is a complete copy of the prior application and drawings, as originally
`filed. The attached papers are a true copy of prior Application No. 11/919,678,
`which is a National Stage Entry of International Application
`No. PCT/JP2006/31 0571, filed May 26, 2006, which claims priority to Japanese
`Patent Application No. 2005-153508, filed May 26, 2005, the content of each of
`which is incorporated herein by reference.
`
`Certification and Request for Prioritized Examination under 37 C.F.R. § 1.102(e)
`
`A Preliminary Amendment is enclosed.
`
`A new oath or declaration is enclosed.
`
`An Application Data Sheet is enclosed.
`
`Par Pharm., Inc.
`Exhibit 1041
`Page 004
`
`

`

`

`

`

`

`PTO/AIA/14 (12-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Pape!Work Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Application Data Sheet 37 CFR 1. 76
`
`Attorney Docket Number
`
`05273.0147-01000
`
`Application Number
`
`Title of Invention I PHARMACEUTICAL COMPOSITION
`
`The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the
`bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76.
`This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the
`document may be printed and included in a paper filed application.
`
`Secrecy Order 37 CFR 5.2
`In Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to
`l..=.=__ 37 CFR 5.2 (Paper filers only_ Applications that fall under Secrecy Order may not be filed electronically.)
`
`Inventor Information:
`
`Inventor
`1
`Legal Name
`
`Prefix Given Name
`
`Kazuyuki
`
`I Remove I
`
`Middle Name
`
`Family Name
`
`FUJIHARA
`
`Suffix
`
`Residence Information (Select One) 0 US Residency @ Non US Residency 0 Active US Military Service
`lJP
`City
`!country of Residence i
`
`Suzuka-shi, Mie-ken
`
`Mailing Address of Inventor:
`
`Address 1
`
`Address 2
`I OSAKA
`City
`Postal Code
`
`DAINIPPON SUMITOMO PHARMA CO., LTD
`
`6-8, DOSHO-MACHI2-CHOME, CHUO-KU OSAKA-SHI
`
`1 541-8524
`
`I State/Province
`I Countryi
`I JP
`
`I
`
`All Inventors Must Be Listed - Additional Inventor Information blocks may be
`generated within this form by selecting the Add button.
`
`I Add I
`
`Correspondence Information:
`Enter either Customer Number or complete the Correspondence Information section below.
`For further information see 37 CFR 1.33(a).
`D An Address is being provided for the correspondence Information of this application.
`Customer Number
`22852
`
`Email Address
`
`Application Information:
`
`Title of the Invention
`
`PHARMACEUTICAL COMPOSITION
`
`Attorney Docket Number 05273.0147-01000
`
`Application Type
`
`Subject Matter
`
`Nonprovisional
`
`Utility
`
`Total Number of Drawing Sheets (if any)
`
`I 3
`
`EFS Web 2.2.11
`
`I I Add Email I
`
`!Remove Email I
`
`I Small Entity Status Claimed D
`
`I Suggested Figure for Publication (if any) I
`
`Par Pharm., Inc.
`Exhibit 1041
`Page 007
`
`

`

`PTO/AIA/14 (12-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Application Data Sheet 37 CFR 1.76
`Title of Invention I PHARMACEUTICAL COMPOSITION
`
`Application Number
`
`Attorney Docket Number
`
`05273.0147-01000
`
`Filing By Reference :
`Only complete this section when filing an application by reference under 35 U.S.C. 111 (c) and 37 CFR 1.57(a). Do not complete this section if
`application papers including a specification and any drawings are being filed. Any domestic benefit or foreign priority information must be
`provided in the appropriate section(s) below (i.e., "Domestic Benefit/National Stage Information" and "Foreign Priority Information").
`
`For the purposes of a filing date under 37 CFR 1.53(b), the description and any drawings of the present application are replaced by this
`reference to the previously filed application, subject to conditions and requirements of 37 CFR 1.57(a).
`Filing date (YYYY-MM-DD)
`
`Intellectual Property Authority or Country
`
`Application number of the previously
`filed application
`
`i-
`
`Publication Information:
`D
`Request Early Publication (Fee required at time of Request 37 CFR 1.219)
`Request Not to Publish. I hereby request that the attached application not be published under
`35 U.S.C. 122(b) and certify that the invention disclosed in the attached application has not and will not be the
`subject of an application filed in another country, or under a multilateral international agreement, that requires
`publication at eighteen months after filing.
`
`D
`
`Representative Information:
`
`Representative information should be provided for all practitioners having a power of attorney in the application. Providing
`this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32).
`Either enter Customer Number or complete the Representative Name section below. If both sections are completed the customer
`Number will be used for the Representative Information during processing.
`
`~se Select One:
`
`omer Number
`
`@ Customer Number
`22852
`
`I 0 US Patent Practitioner IO Limited Recognition (37 CFR 11.9)
`
`Domestic Benefit/National Stage Information:
`This section allows for the applicant to either claim benefit under 35 U.S. C. 119{e), 120, 121, or 365(c) or indicate National Stage
`entry from a PCT application. Providing this information in the application data sheet constitutes the specific reference required
`by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78.
`When referring to the current application, please leave the application number blank.
`
`Prior Application Status
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`11919678
`
`a 371 of international
`
`JP2006310571
`
`Prior Application Status Pending
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`I Remove I
`Filing Date (YYYY-MM-DD)
`
`2006-05-26
`I Remove I
`Filing Date (YYYY-MM-DD)
`
`EFS Web 2.2.11
`
`Par Pharm., Inc.
`Exhibit 1041
`Page 008
`
`

`

`PTO/AIA/14 (12-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`05273.0147-01000
`
`Application Number
`
`Title of Invention
`
`PHARMACEUTICAL COMPOSITION
`
`Additional Domestic Benefit/National Stage Data may be generated within this form
`by selecting the Add button.
`
`Foreign Priority Information:
`
`This section allows for the applicant to claim priority to a foreign application. Providing this information in the application data sheet
`constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.5_5(d). When priority is claimed to a foreign application
`that is eligible for retrieval under the priority document exchange program (PDX)1 the information will be used by the Office to
`automatically attempt retrieval pursuant to 37 CFR 1.55(h)(1) and (2). Under the POX program, applicant bears the ultimate
`responsibility for ensuring that a copy of the foreign application is received by the Office from the participating foreign intellectual
`property office, or a certified copy of the foreign priority application is filed, within the time period specified in 37 CFR 1.55(g)(1 ).
`
`Application Number
`
`Countryi
`
`Filing Date (YYYY-MM-DD)
`
`Access Codei (if applicable)
`
`1 Remove. I
`
`2005-05-26
`JP
`2005-153508
`Additional Foreign Priority Data may be generated within this form by selecting the
`Add button.
`
`Statement under 37 CFR 1.55 or 1.78 for AlA (First Inventor to File) Transition
`Applications
`
`E}his application (1) claims priority to or the benefit of an application filed before March 16, 2013 and (2) also
`
`ontains, or contained at any time, a claim to a claimed invention that has an effective filing date on or after March
`6, 2013.
`NOTE: By providing this statement under 37 CFR 1.55 or 1.78, this application, with a filing date on or after March
`6, 2013, will be examined under the first inventor to file provisions of the AlA.
`
`Authorization to Permit Access:
`[!Zi Authorization to Permit Access to the Instant Application by the Participating Offices
`
`EFS Web 2.2.11
`
`Par Pharm., Inc.
`Exhibit 1041
`Page 009
`
`

`

`PTO/AIA/14 (12-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Application Data Sheet 37 CFR 1.76
`Title of Invention I PHARMACEUTICAL COMPOSITION
`
`Application Number
`
`Attorney Docket Number
`
`05273.0147-01000
`
`If checked, the undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO),
`the Japan Patent Office (JPO). the Korean Intellectual Property Office (KIPO), the World Intellectual Property Office (WI PO),
`and any other intellectual property offices in which a foreign application claiming priority to the instant patent application
`is filed access to the instant patent application. See 37 CFR 1.14(c) and (h). This box should not be checked if the applicant
`does not wish the EPO, JPO, KIPO, WIPO, or other intellectual property office in which a foreign application claiming priority
`to the instant patent application is filed to have access to the instant patent application.
`
`In accordance with 37 CFR 1.14(h)(3), access will be provided to a copy of the instant patent application with respect
`to: 1) the instant patent application-as-filed; 2) any foreign application to which the instant patent application
`claims priority under 35 U .S.C. 119(a)-(d) if a copy of the foreign application that satisfies the certified copy requirement of
`37 CFR 1.55 has been filed in the instant patent application; and 3) any U.S. application-as-filed from which benefit is
`sought in the instant patent application.
`
`In accordance with 37 CFR 1.14(c), access may be provided to information concerning the date of filing this Authorization.
`
`Applicant Information:
`
`Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR
`to have an assignment recorded by the Office.
`
`Applicant 1
`If the applicant is the inventor (or the remaining joint inventor or inventors under 37 CFR 1.45), this section should not be completed.
`The information to be provided in this section is the name and address of the legal representative who is the applicant under 37 CFR
`1.43; or the name and address of the assignee, person to whom the inventor is under an obligation to assign the invention, or person
`who otherwise shows sufficient proprietary interest in the matter who is the applicant under 37 CFR 1.46. If the applicant is an
`applicant under 37 CFR 1.46 (assignee, person to whom the inventor is obligated to assign, or person who otherwise shows sufficient
`proprietary interest) together with one or more joint inventors. then the joint inventor or inventors who are also the applicant should be
`identified in this section.
`
`I Clear I
`lo Joint Inventor
`
`lo Legal Representative under 35 U.S.C. 117
`® Assignee
`lo
`0 Person to whom the inventor is obligated to assign.
`If applicant is the legal representative, indicate the authority to file the patent application, the inventor is:
`I
`
`Person who shows sufficient proprietary interest
`
`I
`
`Name of the Deceased or Legally Incapacitated Inventor :I
`[gJ
`If the Applicant is an Organization check here.
`I DAINIPPON SUMITOMO PHARMA CO., LTD
`Mailing Address Information For Applicant:
`
`Organization Name
`
`Address 1
`
`Address 2
`
`City
`Country' I JP
`Phone Number
`
`EFS Web 2.2.11
`
`6-8, DOSHO-MACHI 2-CHOME, CHUO-KU OSAKA-SHI
`
`OSAKA
`
`I
`
`State/Province
`
`Postal Code
`
`Fax Number
`
`541-8524
`
`Par Pharm., Inc.
`Exhibit 1041
`Page 010
`
`

`

`PTO/AIA/14 (12-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`05273.0147-01000
`
`Application Number
`
`Title of Invention
`
`\ PHARMACEUTICAL COMPOSITION
`
`I Email Address
`~Additional Applicant Data may be generated within this form by selecting the Add button.
`
`Assignee Information including Non-Applicant Assignee Information:
`
`Providing assignment information in this section does not subsitute for compliance with any requirement of part 3 of Title 37 of CFR to
`have an assignment recorded by the Office.
`
`Assignee 1
`
`Complete this section if assignee information, including non-applicant assignee information, is desired to be included on the patent
`application publication . An assignee-applicant identified in the "Applicant Information" section will appear on the patent application
`publication as an applicant. For an assignee-applicant, complete this section only if identification as an assignee is also desired on the
`patent application publication.
`
`If the Assignee or Non-Applicant Assignee is an Organization check here.
`
`~
`
`Organization Name
`
`1
`Mailing Address Information For Assignee including Non-Applicant Assignee:
`
`Address 1
`
`Address 2
`
`City
`
`Countryi
`
`I
`
`Phone Number
`
`State/Province
`
`Postal Code
`
`Fax Number
`
`Email Address
`
`Additional Assignee or Non-Applicant Assignee Data may be generated within this form by
`selecting the Add button.
`
`Signature:
`NOTE: This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4 for signature requirements and
`certifications.
`
`CIU'~ E:. va..... -t+uv~
`I Last Name I Van Horn
`Additional Signature may be generated within this form by selecting the Add button.
`
`Signature
`
`First Name
`
`Charles
`
`Date (YYYY-MM-DD) 2014-02-18
`
`Registration Number
`
`40266
`
`EFS Web 2.2.11
`
`Par Pharm., Inc.
`Exhibit 1041
`Page 011
`
`

`

`PTO/AIA/14 (12-13}
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`05273.0147-01000
`
`Application Number
`
`Title of Invention
`
`PHARMACEUTICAL COMPOSITION
`
`This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which
`is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This
`collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data
`sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to
`complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and
`Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR
`COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
`
`EFS Web 2.2.11
`
`Par Pharm., Inc.
`Exhibit 1041
`Page 012
`
`

`

`Privacy Act Statement
`
`The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to
`a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection
`of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is
`used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not
`furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may
`result in termination of proceedings or abandonment of the application or expiration of the patent.
`
`The information provided by you in this form will be subject to the following routine uses:
`
`1..
`
`The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552)
`and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine
`whether the Freedom of Information Act requires disclosure of these records.
`
`2.
`
`A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or
`administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
`
`3.
`
`4.
`
`5.
`
`6.
`
`7.
`
`8.
`
`A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an
`individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of
`the record.
`
`A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in
`order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as
`amended, pursuant to 5 U.S.C. 552a(m).
`
`A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed,
`as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Co operation Treaty.
`
`A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security
`review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
`
`A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee,
`during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records
`management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the
`GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such
`disclosure shall not be used to make determinations about individuals.
`
`A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuan
`to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37
`CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were
`terminated and which application is referenced by either a published application, an application open to public inspections or an issued
`patent.
`
`9.
`
`A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the
`USPTO becomes aware of a violation or potential violation of law or regulation.
`
`EFS Web 2.2.11
`
`Par Pharm., Inc.
`Exhibit 1041
`Page 013
`
`

`

`Doc Code: PA ..
`Document Description: Power of Attorney
`
`PTO/AIA/82A (07-13)
`Approved for use through 11/30/2014. OMB 0651-0051
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
`
`TRANSMITTAL FOR POWER OF ATTORNEY TO ONE OR MORE
`REGISTERED PRACTITIONERS
`
`NOTE: This form is to be submitted with the Power of Attorney by Applicant form (PTO/AIA/828) to identify the application to which the
`Power of Attorney is directed, in accordance with 37 CFR 1.5, unless the application number and filing date are identified in the Power of
`Attorney by Applicant form. If neither form PTO/AIA/82A nor form PTO/AIA82B identifies the application to which the Power of Attorney is
`directed, the Power of Attorney will not be recognized in the application.
`
`Application Number
`
`Filing Date
`
`First Named Inventor
`
`February 18, 2014
`
`Kazuyuki FUJIHARA
`
`Title
`
`PHARMACEUTICAL COMPOSITION
`
`Art Unit
`
`to be assigned
`to be assigned
`Attorney Docket Number 05273.014 7-01
`
`Examiner Name
`
`SIGNATURE of Applicant or Patent Practitioner
`Signature ~ G'VOt.-~
`Charles E. Van Horn
`
`Name
`
`Date (Optional) 02-18-2014
`40,266
`
`Registration
`Number
`
`Title (if Applicant is a
`juristic entity)
`
`Applicant Name (if Applicant is a juristic entity)
`
`I
`
`NOTE: This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4(d) for signature requirements and certifications. If
`more than one applicant, use multiple forms.
`1
`
`l.f I *Total of
`
`forms are submitted.
`
`This collection of information is required by 37 CFR 1.131, 1.32, and 1.33. The information is required to obtain or retain a benefit by
`the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR
`1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed
`application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require
`to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and
`Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR
`COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
`
`If you need assistance in completing the form, cai/1-800-PT0-9199 and select option 2.
`
`Par Pharm., Inc.
`Exhibit 1041
`Page 014
`
`

`

`Doc Code: PA ..
`Document Description: Power of Attorney
`
`PTOIAIA/828 (07·13)
`Approved lor uu through 111301201<4. OMB 0651-0051
`U.S. Plllentand Trademark Ollice; U.S. DEPARTMENT OF COMMERCE
`Under the PIIP'IfWOrk Reduction Act of 1985, no person. 11re required to reopond to a oolec:tion of lnlormllllon unleeelt diiiJUya a valid OMB conlrOI number
`
`(
`
`POWER OF ATTORNEY BY APPLICANT
`
`]
`
`I hereby revoke aH previous powers of attorney given in the application identified in either the attached transmittal letter or
`the boxes below.
`
`IAppii~U...Numb.,
`
`I, .......
`
`-~--·
`
`I
`(Note: The boxes above may be left blank if infom1ation is provided on fom1 PTO/AIA/82A.)
`[{] I hereby appoint the Patent Practitioner(s) associated with the following Customer Number as my/our attomey(s) or agent(s), and
`the attached transmittal letter (fom1 PTO/AIA/82A) or identified above: I
`to transact all business in the United States Patent and Trademark Office connected therewith for the application referenced in
`I
`~~ --
`M
`D I hereby appoint Practitioner(s) named in the attached list (form PTO/AIAI82C) as my/our attomey(s) or agent(s), and to transact
`
`all business in the United States Patent and Trademark Office connected therewith for the patent application referenced in the
`attached transmittal letter (fom1 PTO/AIAI82A) or identified above. (Note: Complete fom1 PTO/AIAI82C.)
`
`Please recognize or change the correspondence address for the application Identified In the attached transmittal
`letter or the boxes above to:
`[i] The address associated with the above-mentioned Customer Number
`D The address associated with Customer Number: I
`OR
`
`I
`
`OR
`Firm or
`Individual Name
`
`Addrass
`City
`Country
`Telephone
`
`I Email
`I
`I am the Applicant (if the Applicant is a juristic entity, list the Applicant name in the box):
`
`I State
`
`I
`
`I Zip
`
`I
`
`I
`
`loainippon Sumitomo Pharma Co., Ltd.
`D Inventor or Joint Inventor (title not required below)
`D legal Representative of a Deceased or legally Incapacitated Inventor (title not required below)
`[l] Assignee or Person to Whom the Inventor is Under an Obligation to Assign (provide signer's title if applicant is a juristic entity)
`D Person Who Otherwise Shows Sufficient Proprietary Interest (e.g., a petition under 37 CFR 1.46(b)(2) was granted in the
`application or is concurrently beina filed with this document) (provide sianer's title if applicant is a iuristic entity)
`SIGNATURE of Applicant for Patent
`The undersigned (whose tit~pplled be12)11) Is ~rlzed to act on behalf of the applicant (e.g., where the applicant Is e juristic entity).
`/ ,
`MJate (Optional) l7;2.VV<-"•"'-" 1.).
`'/ Signature
`~JI..f>
`I
`Name
`Masayo TAOA
`Title
`Representative Director, President and Chief Executive Officer
`~ Signature -This form must be signed by the applicant In accordance with 37 CFR 1.33. See 37 CFR 1.4 for signature requirements
`and certifications. If more than one applicant, use multiple forms.
`0Totalof 1
`fom1s are submitted.
`This collecloon ollnlonnatlon II requlr..:l by 37 CFR 1.131. 1.32,- 1.33. Thelnlorrnllllon 11 required to obtlln or retain a benefit by the public which leto file (and by the
`USPTOto procen) an application. Conftdentiallty II governed by 35 U.S.C.122 and 37 CFR 1.11 .,d 1.14. Thll ooledlon io elllmllled totllke 3 mlnuteeto complete.
`Including gathering. preparing, and oubmllling the compleled applcatlon form to the USPTO. Time wtllwry depending upon the lndilllduel caae. Any comments on the amount
`of lime you require to complcllo thit form endlor auggeetlona for reducing this buRien, should boaont to the Chief lniOIIlllllion Ofll<;er. U.S. Plllent and Trademark Qlllce, U.S.
`DepartmentoiCommen:e. P.O. Box 1<450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner
`fot Patent., P.O. l!lox 1<4111, Alaxanclrla. VA 22313·1410.
`If you nsed esslatance In completing the fonn, ce/11-800-PT0-9199 and select option 2.
`
`"
`
`Par Pharm., Inc.
`Exhibit 1041
`Page 015
`
`

`

`- -
`
`AlA DECLARATION FOR UTILITY OR
`DESIGN PATENT APPLICATION
`(37 CFR 1.63)
`
`ATTORNEY DOCKET
`NUMBER
`
`05273.0147-01000
`
`I
`
`FIRST NAMED INVENTOR
`
`KAZUYUKI FUJIHARA
`
`IZ1 DECLARATION
`SUBMITTED
`WITH INITIAL
`FILING
`
`I
`
`I
`
`OR
`
`I
`COMPLETE IF KNOWN
`
`I
`
`D DECLARATION
`SUBMITTED
`AFTER INITIAL
`FILING
`(SURCHARGE (37
`CFR 1.16(F))
`REQUIRED
`
`APPLICATION NUMBER
`
`FILING DATE
`
`ART UNIT
`
`EXAMINER NAME
`
`I
`!
`
`UNASSIGNED
`
`UNASSIGNED
`
`UNASSIGNED
`
`UNASSIGNED
`
`PHARMACEUTICAL COMPOSITION
`
`(Title of the Invention)
`As a below named inventor, I hereby declare that: (1) This declaration is directed to the application which !ZI is attached and/or D was
`filed on February_, 2014, as United States Application No.
`(Confirmation No. __ ), or PCT International Application No.
`[Text]; (2) the application was made or authorized to be made by me; (3) my residence and mailing address are as stated below next to
`my name; and (4) I believe I am the original inventor or an original joint inventor of a claimed invention in the application.
`
`As a below named inventor, I have reviewed and understand the contents of the application, including the claims, and am aware of the
`duty to disclose to the USPTO all information known to me to be material to patentability as defined in 37C.F .R. § 1.56.
`
`Authorization To Permit Access To Application by Participating Offices:
`
`1Z1
`If checked, the undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO), the Japan Patent
`Office (JPO), the Korean Intellectual Property Office (KIPO), the World Intellectual Property Office (WIPO), and any other intellectual
`property offices in which a foreign application claiming priority to the above-identified patent application is filed access to the above(cid:173)
`identified patent application. See 37 CFR 1.14(c) and (h). This box should not be checked if the Applicant does not wish the EPO, JPO,
`KIPO, WIPO, or other intellectual property office in which a foreign application claiming priority to the above-identified application is filed to
`have access to the above identified patent application.
`
`In accordance \vith 37 CFR 1.14(h)(3), access will be provided to a copy of the above-identified patent application with respect to: 1) the
`above-identified patent application-as-filed; 2) any foreign application to which the above-identified patent application claims priority under
`35 U .S.C. 119(a)-(d) if a copy of the foreign application that satisfies the certified copy requirement of 37 CFR 1.55 has been filed in the
`above-identified patent application; and 3) any U.S. application-as-filed from which benefit is sought in the above-identified patent
`application.
`
`In accordance with 37 CFR 1.14(c), access may be provided to information concerning the date of filing the Authorization to Permit Access
`to Application by Participating Offices.
`
`I hereby acknowledge that any willful false statements made in this declaration are punishable by fine or imprisonment of not more than
`five (5) years, or both, under section 1001 ofTitle 18 of the United States Code.
`
`Legal Name of First Inventor
`Kazuyuki Fujihara
`Residence
`Suzuka-shi, Mie-ken, Japan
`Mailing Address
`c/o DAINIPPON SUMITOMO PHARMA CO., LTD., 6-8, DOSHO-MACHI2·CHOME, CHUO-KU, OSAKA-SHI, OSAKA,
`JP 541-8524
`
`I Date
`1~)), /2
`
`)_i;,./ y
`
`.
`
`l
`
`I Signature /-c'. ,
`
`1L~t
`.;
`
`•, h(i
`
`Page 1 of 2
`
`FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.LP.
`
`Par Pharm., Inc.
`Exhibit 1041
`Page 016
`
`

`

`I Signature
`
`I Signature
`
`I Signature
`
`I Signature
`
`I Signature
`
`I Signature
`
`I Signature
`
`I Signature
`
`Legal Name of Second Inventor
`[Text]
`Residence
`[Text]
`Mailing Address
`[Text]
`Legal Name of Third Inventor
`[Text]
`Residence
`[Text]
`Mailing Address
`[Text]
`Legal Name of Fourth Inventor
`[Text]
`Residence
`[Text]
`Mailing Address
`[Text]
`Legal Name of Fifth Inventor
`[Text]
`Residence
`[Text]
`Mailing Address
`[Text]
`Legal Name of Sixth Inventor
`[Text]
`Residence
`[Text]
`II Mailing Address
`[Text]
`Legal Name of Seventh Inventor
`[Text]
`Residence
`[Text]
`Mailing Address
`[Text]
`Legal N